Latest Oncology News

Polatuzumab Shows Improved Survival and Complete Responses in R/R DLBCL

July 06, 2022

Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Bishop Reviews Risk Assessment and Treatment for GVHD

July 06, 2022

Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.

VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC

July 05, 2022

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.